Skip to main content

Advertisement

SpringerLink
Log in

Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

The objective of this study was to determine the predictors of successful treatment of lower urinary tract disorders with sacral nerve stimulation (SNS) and the rate of adverse events and reoperations.

Methods

A retrospective case series of patients who underwent SNS at a single institution was analyzed.

Results

Seventy-six patients underwent stage I trial of SNS. Fifty-eight (76%) patients experienced improvement and underwent placement of an implantable pulse generator with a mean follow-up of 23.7 months (SD ± 22.3). Surgical revisions occurred in 14/58 (24%) patients and 15/58 (26%) patients had the device explanted after a mean of 2.8 years (SD ± 1.7). Patients with greater than ten incontinence episodes per day were more likely to have a successful stage I trial compared to those with less than five (OR = 10.3; 95% CI 2.1 to 50.60).

Conclusions

Although SNS is a safe and effective therapy for lower urinary tract disorders, it is associated with a high reoperation rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Steers WD, Herschorn S, Kreder KJ et al (2007) Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 100(2):337–45

    Article  PubMed  CAS  Google Scholar 

  2. Hu T, Wagner TH, Bentkover JD et al (2003) Estimated economic costs of overactive bladder in the United States. Urology 61(6):1123–1128

    Article  PubMed  Google Scholar 

  3. Abrams P, Freeman R, Anderstrom C, Mattiason A (1998) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81:801–810

    Article  PubMed  CAS  Google Scholar 

  4. Tanagho EA, Schmidt RA (1988) Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 140:1331–9

    PubMed  CAS  Google Scholar 

  5. Brazzelli M, Murray A, Fraser C (2006) Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 175(3):835–841

    Article  PubMed  Google Scholar 

  6. Aboseif S, Tamaddon K, Chalfin S, Freedman S, Kaptein J (2002) Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. Urology 60(1):52–56

    Article  PubMed  Google Scholar 

  7. Amundsen C, Romero AA, Jaminson MG, Webster GD (2005) Sacral neuromodulation for intractable urge incontinence: are there factors associated with a cure? Urology 66:746–750

    Article  PubMed  Google Scholar 

  8. Wallace PA, Lane FL, Noblett KL (2007) Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 197(1):96.e1-1–96.e1-5

    Google Scholar 

  9. Uebersax JS, Wyman JF, Shumaker SA et al (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14:131–9

    Article  PubMed  CAS  Google Scholar 

  10. Schmidt RA, Jonas U, Oleson KA et al (1999) Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol 162:352

    Article  PubMed  CAS  Google Scholar 

  11. Bump RC, Mattiasson A, Bo K et al (1996) The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 175:10–17

    Article  PubMed  CAS  Google Scholar 

  12. Haylen BT, de Ridder D, Freeman RM et al (2010) An international urogynecologic association (IUGA/ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourolog Urodyn 29(1):4–20

    Google Scholar 

  13. Kessler T, Framboise DL, Trelle S et al (2010) Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systemic review and meta-analysis. Eur Urol 58(6):865–74

    Article  PubMed  Google Scholar 

  14. Goh M, Diokno AC (2007) Sacral neuromodulation for nonobsrtuctive urinary retention—is success predictable? J Urology 178:197–19913

    Article  Google Scholar 

  15. Scheepens WA, Jongen GJ, Neiman FHM et al (2002) Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction. Urology 60(4):598–602

    Article  PubMed  CAS  Google Scholar 

  16. Shumaker SA, Wyman JF, Uebersax JS et al (1994) Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 3:291–306

    Article  PubMed  CAS  Google Scholar 

  17. Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB et al (2000) Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 56(6):87–91, suppl.1

    Article  PubMed  CAS  Google Scholar 

  18. Bosch JL (2010) An update on sacral neuromodulation: where do we stand with this in the management of lower tract dysfunction in 2010? BJU 106(10):1432–42

    Article  Google Scholar 

  19. Hijaz A, Sandip VP, Daneshgari F, Frinjari H, Goldman H, Rackley R (2006) Complications and troubleshooting of two-staged sacral neuromodulation therapy: a single institutions experience. Urology 68(3):533–537

    Article  PubMed  Google Scholar 

  20. White WM, Mobley JD, Doggweiler R, Dobmeyer-Dittrich C, Klein FA (2009). Incidence and predictors of complications with sacral neuromodulation. 73(4);731-35

Download references

Acknowledgment

We would like to acknowledge the AUGS Foundation for their support.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Division of Female Pelvic Medicine and Reconstructive Surgery, David Geffen UCLA School of Medicine, 1000 W. Carson St, Torrance, CA, 90509, Box 489, USA

    Tajnoos Yazdany, Narender Bhatia & John Nguyen

  2. Division of Female Pelvic Medicine and Reconstructive Surgery, Harbor UCLA Medical Center, 1000 W. Carson St, Torrance, CA, 90509, Box 489, USA

    Tajnoos Yazdany, Narender Bhatia & John Nguyen

  3. Kaiser Permanente Downey Medical Center, 9449 E. Imperial Hwy., C327, Downey, CA, 90242, USA

    John Nguyen

Authors
  1. Tajnoos Yazdany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Narender Bhatia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tajnoos Yazdany.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yazdany, T., Bhatia, N. & Nguyen, J. Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women. Int Urogynecol J 22, 1549–1554 (2011). https://doi.org/10.1007/s00192-011-1512-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-011-1512-2

Keywords

Search

Navigation